Valeant Pharmaceuticals Announces 2013 Annual Meeting Results

News provided by

Valeant Pharmaceuticals International, Inc.

May 21, 2013, 05:00 ET

LAVAL, Quebec, May 21, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2013 annual meeting of shareholders today.  The detailed results of the vote for the election of directors are set out below: 

Name

For

Withheld






Ronald H. Farmer

235,731,934

1,964,748

Robert A. Ingram

233,865,876

3,830,806

Theo Melas-Kyriazi

237,081,508

615,174

G. Mason Morfit

235,623,283

2,073,399

J. Michael Pearson

232,521,825

5,174,857

Robert N. Power

235,168,850

2,527,832

Norma A. Provencio

237,125,741

570,941

Howard B. Schiller

221,521,559

16,175,123

Lloyd M. Segal

236,082,529

1,614,153

Katharine Stevenson

234,501,146

3,195,536

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2014 annual meeting of shareholders; and approved the continuance of the Company from the Canada Business Corporations Act to the British Columbia Business Corporations Act.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
[email protected]

SOURCE Valeant Pharmaceuticals International, Inc.